Teleflex Incorporated’s (TFX - Free Report) shares lost 7.6% to close at $250.51 after it announced earnings results on Mar 5. The company reported adjusted earnings per share of $2.44 in fourth-quarter 2017, beating the Zacks Consensus Estimate of $2.40. Earnings improved 14.6% from the year-ago figure of $2.13.
Revenues in Detail
Adjusted revenues in the fourth quarter increased 15.8% year over year to $595.1 million (12.6% at constant exchange rate or CER) but missed the Zacks Consensus Estimate of $602 million owing to some temporary softness.
On a segmental basis, Vascular North America revenues increased 0.5% (0.3% at CER) year over year in the fourth quarter to $80.7 million.
Interventional North America revenues increased 177.6% in the fourth quarter from the year-ago quarter (177.2% at CER) to $61.7 million.
Anesthesia North America revenues were down 9.2% from the year-ago quarter (down 9.4% at CER) to $49.9 million.
Surgical North America revenues in the fourth quarter were down 9.4% from the year-ago quarter (9.8% at CER) to $43.7 million.
EMEA revenues increased 5.8% from the year-ago quarter but fell 2% at CER to $143.6 million. Asia revenues rose 8% in the quarter from the year-ago quarter (4.5% at CER) to $78.8 million. OEM revenues climbed 1.3% from the year-ago quarter but declined 0.1% at CER to $46 million.
All other revenues increased 67% (67.6% at CER) to $90.7 million in the quarter under review.
Operational Update
Teleflex's gross profit during the reported quarter increased 21.1% year-over-year to $330.7 million. Gross margin expanded 245 basis points (bps) to 55.6%.
SG&A expenses in the fourth quarter rose 47.9% year over year to $213.3 million. Research and development expenses rose 62.4% year over year to $25.5 million. Operating expenses totaled $238.8 million in the fourth quarter, up 49.3% year over year.
Adjusted operating margin in the quarter was 15.5%, down 657 bps from the year-ago quarter.
Financial Update
Teleflex exited 2017 with cash and cash equivalents of $333.6 million, compared with $543.8 million at the end of 2016.
2017 at a Glance
Full-year adjusted earnings came in at $8.40 compared with the year-ago figure of $7.34, reflecting an increase of 14.4%.
Full-year adjusted revenues came in at $2146.3 million, up 14.9% from the year-ago period.
2018 Guidance
For 2018, Teleflex expects adjusted revenues growth at CER in the band of 12-13%. The company also expects adjusted earnings per share in the band of $9.55-$9.75. The Zacks Consensus Estimate for full-year earnings per share is pegged at $9.68, within the company’s guided range. The Zacks Consensus Estimate for full-year revenues stands at $2.46 billion.
Our Take
Teleflex exitedfourth-quarter 2017 on a mixed note. We are encouraged to note that the company is working on product innovation through R&D. However, the contraction in operating margin is discouraging. Also, a tough competitive landscape acts as a dampener.
Zacks Rank & Key Picks
Teleflex has a Zacks Rank #3 (Hold).
A few better-ranked stocks that reported solid results this earnings season are PetMed Express (PETS - Free Report) , PerkinElmer and ResMed (RMD - Free Report) . While PetMed sports a Zacks Rank #1 (Strong Buy), PerkinElmer and ResMed carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported third-quarter fiscal 2018 results. Adjusted earnings per share were 44 cents, up 88.3% from the prior-year quarter. Revenues rose 13.7% on a year-over-year basis to $60.1 million.
PerkinElmer reported fourth-quarter 2017 adjusted earnings per share of 97 cents. Adjusted revenues were approximately $641.6 million, up from $567 million in the year-ago quarter.
ResMed posted second-quarter fiscal 2018 adjusted earnings per share of $1, up 36.9% from the prior-year quarter. Revenues in the reported quarter increased 13.4% year over year (up 11% at constant exchange rate or CER) to $601.3 million.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Teleflex Incorporated’s (TFX - Free Report) shares lost 7.6% to close at $250.51 after it announced earnings results on Mar 5. The company reported adjusted earnings per share of $2.44 in fourth-quarter 2017, beating the Zacks Consensus Estimate of $2.40. Earnings improved 14.6% from the year-ago figure of $2.13.
Revenues in Detail
Adjusted revenues in the fourth quarter increased 15.8% year over year to $595.1 million (12.6% at constant exchange rate or CER) but missed the Zacks Consensus Estimate of $602 million owing to some temporary softness.
On a segmental basis, Vascular North America revenues increased 0.5% (0.3% at CER) year over year in the fourth quarter to $80.7 million.
Interventional North America revenues increased 177.6% in the fourth quarter from the year-ago quarter (177.2% at CER) to $61.7 million.
Anesthesia North America revenues were down 9.2% from the year-ago quarter (down 9.4% at CER) to $49.9 million.
Surgical North America revenues in the fourth quarter were down 9.4% from the year-ago quarter (9.8% at CER) to $43.7 million.
EMEA revenues increased 5.8% from the year-ago quarter but fell 2% at CER to $143.6 million. Asia revenues rose 8% in the quarter from the year-ago quarter (4.5% at CER) to $78.8 million. OEM revenues climbed 1.3% from the year-ago quarter but declined 0.1% at CER to $46 million.
All other revenues increased 67% (67.6% at CER) to $90.7 million in the quarter under review.
Operational Update
Teleflex's gross profit during the reported quarter increased 21.1% year-over-year to $330.7 million. Gross margin expanded 245 basis points (bps) to 55.6%.
SG&A expenses in the fourth quarter rose 47.9% year over year to $213.3 million. Research and development expenses rose 62.4% year over year to $25.5 million. Operating expenses totaled $238.8 million in the fourth quarter, up 49.3% year over year.
Adjusted operating margin in the quarter was 15.5%, down 657 bps from the year-ago quarter.
Financial Update
Teleflex exited 2017 with cash and cash equivalents of $333.6 million, compared with $543.8 million at the end of 2016.
2017 at a Glance
Full-year adjusted earnings came in at $8.40 compared with the year-ago figure of $7.34, reflecting an increase of 14.4%.
Full-year adjusted revenues came in at $2146.3 million, up 14.9% from the year-ago period.
2018 Guidance
For 2018, Teleflex expects adjusted revenues growth at CER in the band of 12-13%. The company also expects adjusted earnings per share in the band of $9.55-$9.75. The Zacks Consensus Estimate for full-year earnings per share is pegged at $9.68, within the company’s guided range. The Zacks Consensus Estimate for full-year revenues stands at $2.46 billion.
Our Take
Teleflex exitedfourth-quarter 2017 on a mixed note. We are encouraged to note that the company is working on product innovation through R&D. However, the contraction in operating margin is discouraging. Also, a tough competitive landscape acts as a dampener.
Zacks Rank & Key Picks
Teleflex has a Zacks Rank #3 (Hold).
A few better-ranked stocks that reported solid results this earnings season are PetMed Express (PETS - Free Report) , PerkinElmer and ResMed (RMD - Free Report) . While PetMed sports a Zacks Rank #1 (Strong Buy), PerkinElmer and ResMed carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported third-quarter fiscal 2018 results. Adjusted earnings per share were 44 cents, up 88.3% from the prior-year quarter. Revenues rose 13.7% on a year-over-year basis to $60.1 million.
PerkinElmer reported fourth-quarter 2017 adjusted earnings per share of 97 cents. Adjusted revenues were approximately $641.6 million, up from $567 million in the year-ago quarter.
ResMed posted second-quarter fiscal 2018 adjusted earnings per share of $1, up 36.9% from the prior-year quarter. Revenues in the reported quarter increased 13.4% year over year (up 11% at constant exchange rate or CER) to $601.3 million.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PETS - FREE
Get the latest research report on RMD - FREE
Get the latest research report on TFX - FREE